We are developing new biologics against protein receptors combining physical models and the limitless power of AI.

Generative AI fails to accurately predict new antibodies. With our technology, we enhance the power of AI to accurately predict the interaction between antibodies and their antigens.

We use the principles of evolution to explore the space of antibody sequences.

Using digital directed evolution, we mimic the process by which the immune system generates new antibodies and find solutions that are not accessible with other technologies.

We distinguish ourselves by bringing to our clients and partners the certainty of a successful discovery program for antibodies against GPCRs.

This class of proteins is associated with major diseases and constitute the central class of targets for which we bring new promising solutions.